Dr. Davids On Ipilimumab for Hematologic Malignancy Treatment

Matthew Davids, MD
Published: Wednesday, Dec 17, 2014



Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses ipilimumab and its potential to treat patients with relapsed hematologic malignancies after donor stem cell transplantation.

Although ipilimumab, was studied several years ago in this space and produced some activity, the study only used a low, single dose treatment plan, Davids says.

In a phase I trial presented at the 2014 ASH Annual Meeting, patients received four doses of ipilimumab, three weeks apart. Patients who responded or had stable disease will then be enrolled on the phase Ib expanded cohort for up to one year of therapy with dosing every three months, Davids says.



Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses ipilimumab and its potential to treat patients with relapsed hematologic malignancies after donor stem cell transplantation.

Although ipilimumab, was studied several years ago in this space and produced some activity, the study only used a low, single dose treatment plan, Davids says.

In a phase I trial presented at the 2014 ASH Annual Meeting, patients received four doses of ipilimumab, three weeks apart. Patients who responded or had stable disease will then be enrolled on the phase Ib expanded cohort for up to one year of therapy with dosing every three months, Davids says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x